



**GSK's graduated approach to
patents and intellectual property
to widen access to medicines in
the world's poorest countries**

Dr Rudy Onia, GSK



Access in the GSK Business Model



Access ~ Innovation

AND not OR



We've turned up the Volume



Access far is more than just about IP



25% price ceiling, tiered and no-profit pricing



20% Re-investment



Open Innovation and Open Data



Graduated approach to IP



Approach to intellectual property will reflect a country's economic maturity

Will not file for patent protection in Least Developed and Low Income Countries

Will seek to grant licences to generic manufacturers to supply versions of GSK medicines in Lower Middle Income Countries

Intend to commit future oncology products to patent pooling and will explore this approach with Medicines Patent Pool in response to increasing burden of cancer in developing countries

Commit to make information about our patent portfolio freely available



Thank You